Targeting unmet
medical needs
through novel therapies
and delivery systems

for patients with
cardiopulmonary diseases

Bellerophon Therapeutics is currently conducting clinical trials in pulmonary arterial hypertension (PAH) and
pulmonary hypertension associated with interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF).